| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4454711
Max Phase: Preclinical
Molecular Formula: C16H24F3N3O6
Molecular Weight: 297.36
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: NC[C@H]1CC[C@@H](COC(=O)NC2CCC(=O)NC2=O)CC1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C14H23N3O4.C2HF3O2/c15-7-9-1-3-10(4-2-9)8-21-14(20)16-11-5-6-12(18)17-13(11)19;3-2(4,5)1(6)7/h9-11H,1-8,15H2,(H,16,20)(H,17,18,19);(H,6,7)/t9-,10+,11?;
Standard InChI Key: GSOOYNWQKINCJY-DIVWUKMWSA-N
Associated Targets(Human)
Cereblon/Casein kinase I alpha 35 Activities
Cereblon/Aiolos 164 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Cereblon isoform 4 52 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 297.36 | Molecular Weight (Monoisotopic): 297.1689 | AlogP: 0.28 | #Rotatable Bonds: 4 |
| Polar Surface Area: 110.52 | Molecular Species: BASE | HBA: 5 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 11.63 | CX Basic pKa: 10.20 | CX LogP: -0.31 | CX LogD: -2.77 |
| Aromatic Rings: 0 | Heavy Atoms: 21 | QED Weighted: 0.65 | Np Likeness Score: -0.22 |
References
| 1. Heim C, Pliatsika D, Mousavizadeh F, Bär K, Hernandez Alvarez B, Giannis A, Hartmann MD.. (2019) De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives., 62 (14): [PMID:31251063] [10.1021/acs.jmedchem.9b00454] |
Source
Source(1):